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Objectives: Peptides derived from the C-terminal heptad repeat (CHR) of HIV-1 gp41 are potent fusion inhibitors.
We have recently demonstrated that the unique M-T hook structure preceding the pocket-binding motif of CHR
peptide-based inhibitors can greatly improve their antiviral activity. In this study, we applied the M-T hook struc-
ture to optimize sifuvirtide (SFT), a potent CHR-derived inhibitor currently under Phase III clinical trials in China.
Methods: The peptide MT-SFT was generated by incorporating two M-T hook residues (Met-Thr) into the
N-terminus of sifuvirtide. Multiple structural and functional approaches were used to determine the biophysical
properties and antiviral activity of MT-SFT.
Results: The high-resolution crystal structure of MT-SFT reveals a highly conserved M-T hook conformation.
Compared with sifuvirtide, MT-SFT exhibited a significant improvement in the ability to bind to the N-terminal
heptad repeat, to block the formation of the six helix bundle and to inhibit HIV-1 Env-mediated cell fusion,
viral entry and infection. Importantly, MT-SFT was fully active against sifuvirtide- and enfuvirtide (T20)-resistant
HIV-1 variants and displayed a high genetic barrier to developing drug resistance.
Conclusions: Our studies have verified that the M-T hook structure offers a general strategy for designing novel
HIV-1 fusion inhibitors and provide new insights into viral entry and inhibition.
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Introduction
More than 60 million people have been infected by HIV-1 and25
million people have died of AIDS-related diseases (www.unaids.
org). Six classes of HIV-1 inhibitors in clinics are directed against
four specific steps of the viral life cycle, including cell entry, reverse
transcription, integration and virion maturation.1,2 Different from
other classes of anti-HIV drugs that act after infection occurs,
HIV-1 entry inhibitors intercept the virus before it invades the target
cells.3,4 Currently, there are two HIV-1 entry inhibitors for clinical
use: maraviroc (UK-427857), approved in 2007, binds to the cell
coreceptor CCR5 thus blocking the binding of virus;5,6 and enfuvir-
tide (T20), a 36 amino acid peptide derived from the C-terminal
heptad repeat (CHR) region of HIV-1 transmembrane protein
gp41 (Figure 1), binds to the N-terminal heptad repeat (NHR) region
of gp41 thus preventing the formation of viral fusion core, the gp41
six helix bundle (6-HB).7 –9 Approved in April 2003, enfuvirtide is the
first and only fusion inhibitor used in combination therapy of HIV-1
infection. However, enfuvirtide requires high dosages and drug
resistance is easily acquired,10– 13 calling for a next generation of
HIV-1 fusion inhibitors.
A series of novel HIV-1 fusion inhibitors have been created
by using the CHR-derived peptide C34 as a template.14 – 16 The
rationale is based on the following: (i) the protease-resistant C34
was used to determine the first gp41 structure (6-HB), thus repre-
senting a core sequence of the CHR;17,18 (ii) C34 contains the NHR
pocket-binding motif at its extreme N-terminus, thus stabilizing the
interaction of inhibitor with the target site;17,19,20 and (iii) C34 has
higher potency than enfuvirtide to inhibit both wild-type and
enfuvirtide-resistant HIV-1 isolates.13,16,21 Based on the three-
dimensional structure of gp41, sifuvirtide (SFT) was designed by
introducing multiple salt bridges into C34 and further incorporating
a serine residue into its N-terminus.22 Compared with its parental
peptide, sifuvirtide exhibited significantly improved antiviral activity
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and pharmaceutical profiles.22 Our crystallographic studies have
provided the structural basis for sifuvirtide, confirming the original
design strategy of the peptide and revealing the key motifs respon-
sible for its stability and antiviral activity.23 Indeed, several novel
interhelix salt bridges and hydrogen bonds improve the binding
affinity of sifuvirtide for the target NHR region and the extra serine
residue stabilizes the N-terminal portion of the peptide.23 Sifuvirtide
has already been advanced into clinical Phase III trials in China.
However, it was also found that sifuvirtide had a relatively low gen-
etic barrier to induction of drug resistance.24 In in vitro selection, a
panel of sifuvirtide-resistant HIV-1 variants could be easily
obtained.24 Similar to enfuvirtide, the responsible mutations of sifu-
virtide resistance were largely mapped to the inhibitor binding sites
in the NHR, which overlapped with enfuvirtide-resistant mutations
either singly or in combination, such as I37T, V38A, N43K and I37T/
N43K (according to HIV-1HXB2 gp41 numbering throughout).
10–12
Therefore, new strategies or concepts are eagerly wanted to
develop HIV-1 fusion inhibitors that not only inhibit the existing
resistant HIV-1 variants but also possess high genetic barriers to
induction of drug resistance.
We previously identified that the CHR-derived peptide CP32 (i.e.
CP621-652) had a much higher binding affinity than C34 for the
NHR target.25 Following that we designed CP32M, which exhibited
a significantly improved anti-HIV activity especially against
enfuvirtide-resistant viruses.26 Recently, we determined the crystal
structure of CP32 and identified that the residues Met115 and
Thr116 preceding the pocket-binding domain (PBD) of the peptide
forms a hook-like structure, named the M-T hook.27 We also
demonstrated that addition of the M-T hook structure to the
N-termini of C34 or the short peptide SC22EK could greatly increase
the binding affinity and antiviral activity of the inhibitors,28,29
addressing the importance of the M-T hook as a vital strategy to
design or optimize HIV-1 fusion inhibitors. In this study, we
engineered sifuvirtide by adding the M-T hook to improve its
pharmaceutical profiles. The high-resolution crystal structures con-
firmed the M-T hook conformation presented at the N-terminus of
sifuvirtide. We demonstrated that the M-T hook structure markedly
enhanced the binding affinity and anti-HIV activity of sifuvirtide,
especially against those sifuvirtide- and enfuvirtide-resistant
HIV-1 mutants. Significantly, the resulting peptide (MT-SFT) had
an increased genetic barrier compared with sifuvirtide to the devel-
opment of resistance.
Materials and methods
Peptide synthesis
The CHR-derived peptides enfuvirtide, sifuvirtide, MT-SFT, C34 and MT-C34
and the NHR-derived peptides N41, N36 and N36 mutants (I37T, V38A,
Q40H, N43K, I37T/N43K and V38A/N42T) were synthesized by a standard
solid-phase Fmoc method as described previously.28 All peptides were
acetylated at the N-terminus and amidated at the C-terminus. They
were purified by reversed-phase HPLC and verified for purity.95% and cor-
rect amino acid composition by mass spectrometry. The concentrations of
the peptides were determined by UV absorbance and a theoretically calcu-
lated molar extinction coefficient 1 (280 nm) of 5500 and 1490 M – 1 cm–1
based on the number of tryptophan and tyrosine residues, respectively.
Structure determination of the 6-HB-containing MT-SFT
In order to determine the crystal structure of 6-HBs formed by MT-SFT/N36
and MT-SFT/N41, MT-SFT peptide and its NHR counterparts (N36 or N41),
synthetic peptides MT-SFT/N36 or MT-SFT/N41 were mixed at 1:1 molar
ratio and were dissolved in denaturing buffer containing 100 mM
NaH2PO4, 10 mM Tris HCl pH 8.0 and 8 M urea, respectively. The refolding
was carried out by dialysis against refolding buffer containing 50 mM
Tris-HCl (pH 7.5), 100 mM NaCl at 48C overnight, yielding soluble 6-HBs.
The 6-HBs were finally purified by size-exclusion chromatography
N36
N41
FP NHR CHR TM
1 16 25 79 117 155 173 195 345
CP
T20
M-T hook
C34
MT-C34
SFT
MT-SFT
Figure 1. Schematic illustration of the HIV-1 gp41 functional domains and the sequences of NHR- or CHR-derived peptides. The gp41 numbering of
HIV-1HXB2 is used. FP, fusion peptide; TM, transmembrane domain; CP, cytoplasmic tail. The sequences corresponding to the NHR pocket region are
shown in blue. The sequences corresponding to the CHR pocket-binding domain are shown in red. The position and sequence for the M-T hook structure
are shown in green.
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(Superdex 75 10/300 GL, GE Healthcare). A predominant peak correspond-
ing to the size of the 6-HB was collected and concentrated prior to crystal-
lization trials. The 6-HB composed of MT-SFT/N36 was crystallized by
mixing equal volumes (1 mL) of the concentrated sample (10 mg/mL)
and reservoir solution containing 0.14 M calcium chloride, 0.1 M sodium
acetate (pH 4.6) and 18% (v/v) 2-propanol at 228C. The cryocooling was
carried out by soaking the crystals for 60 s in reservoir solution containing
15% glycerol followed by flash freezing in liquid nitrogen. The 6-HB com-
posed of MT-SFT/N41 was crystallized by mixing equal volumes (1 mL) of
purified sample (10 mg/mL) and reservoir solution containing 0.1 M
MES buffer pH 6.4, 26% (v/v) PEG 4000 in a hanging drop vapour diffusion
system at 228C. The cryocooling was carried out by soaking the crystals for
40 s in reservoir solution containing 15% glycerol followed by flash freez-
ing in liquid nitrogen. Complete datasets for the MT-SFT/N36 and MT-SFT/
N41 complexes were collected at beamline X10SA, Swiss Light Source at
Paul Scherrer Institute using X-rays with a wavelength of 1.000 A˚. The crys-
tal structure containing MT-SFT/N36 and MT-SFT/N41 was solved by
molecular replacement (Phaser for MR, CCP4 package) using the crystal
structure of sifuvirtide (PDB ID: 3VIE) as the searching models, which yielded
the interpretable electron-density maps. Both structures were refined
(PHENIX) to finalize the atomic models with excellent refinement statistics
and stereochemical qualities and validated by MolProbity analysis (Table S1,
available as Supplementary data at JAC Online). The MolProbity scores for
the crystal structures of the 6-HBs containing MT-SFT/N36 and MT-SFT/
N41 are 1.37 and 1.24, rating 93rd and 96th percentiles among structures
of comparable resolution, respectively. The Ramachandran plots of both
structures find all residues in the favoured area.
Circular dichroism (CD) spectroscopy
CD spectroscopy was performed according to the protocol described pre-
viously.30 Briefly, a CHR peptide (C34, SFTor MT-SFT) was incubated with an
equal molar concentration of NHR peptide N36 or its mutant (I37T, V38A,
Q40H, N43K, I37T/N43K and V38A/N42T) at 378C for 30 min. The final con-
centration of each peptide was 10 mM in PBS buffer (pH 7.2). The CD spec-
tra were acquired on a Jasco spectropolarimeter (model J-815) using a
1 nm bandwidth with a 1 nm step resolution from 195 to 260 nm at
room temperature. The spectra were corrected by subtraction of a blank
corresponding to the solvent. The data were averaged over three accumu-
lations. Thea-helical content was calculated from the CD signal by dividing
the mean residue ellipticity [u] at 222 nm by the value expected for 100%
helix formation (233000 degrees.cm2.dmol21). The thermal denatur-
ation was performed by monitoring the ellipticity [u] at 222 nm from
20–988C using a temperature controller. The temperature was increased
at a rate of 1.28C/min; data were acquired at a 1 nm bandwidth at 222 nm
at a frequency of 0.25 Hz. The melting curve was smoothed and the mid-
point of the thermal unfolding transition (Tm) values was taken as the
maximum of the derivative d[u]222/dT. The Tm value was detected at a
peptide concentration of 10 mM in PBS buffer.
Isothermal titration calorimetry (ITC)
ITC assay was performed using an iTC200 microcalorimeter instrument
(MicroCal, USA) as described previously.28 Briefly, 1 mM N36 dissolved in
double-distilled H2O (ddH2O) was injected into the chamber containing
100 mM sifuvirtide or MT-SFT. The experiments were carried out at 258C.
The time between injections was 240 s and the stirring speed was
500 rpm. The heats of dilution were determined in control experiments
by injecting N36 into ddH2O and subtracted from the heats produced in
the corresponding peptide–peptide binding experiments. Data acquisition
and analysis were performed using MicroCal Origin software (version 7.0).
Cell–cell fusion assays
293Teffector cells seeded in six-well plates at 4×105 cells/well were trans-
fected with the plasmid encoding HIV-1NL4-3 Env. The day after
transfection, the effector cells were incubated with MT-4 cells at a ratio
of 1 :3 in 96-well plates in the presence or absence of tested peptides.
After coculturing for an additional 48 h at 378C, the syncytia of each
well were counted under a microscope. The percentage inhibition of fusion
by the peptides and 50% inhibitory concentration (IC50) values of fusion
were calculated using GraphPad Prism software (GraphPad Software
Inc., San Diego, CA, USA).
HIV-1 single-cycle infection
HIV-1 pseudoviruses were generated as described previously.31 Briefly, 293T
cells were co-transfected with an Env-expressing plasmid and a backbone
plasmid pSG3Denv that encodes Env-defective, luciferase-expressing HIV-1
genome using Lipofectamine 2000 reagent (Invitrogen). Pseudovirus-
containing culture supernatants were harvested 48 h after transfection
and filtered using a 0.45 mm pore size. The 50% tissue culture infectious
dose (TCID50) of the pseudovirus was determined in TZM-bl cells. The inhibi-
tory activity of sifuvirtide and MT-SFT was determined using TZM-bl cells.
Briefly, the peptides were prepared with 10 series dilutions in a 3-fold step-
wise manner and mixed with 100 TCID50 viruses and incubated for 1 h at
room temperature. The mixture was added to TZM-bl cells (104/well) and
incubated at 378C for 48 h before the luciferase activity was measured as
described previously.31
Inhibition of HIV-1NL4-3 infection
The molecular clone of wild-type or drug-resistant HIV-1NL4-3 was prepared
by transfection of pNL4-3 plasmid into 293T cells. The virus stock was
harvested 48 h post-transfection and quantified for TCID50. Inhibition of
infection by sifuvirtide and MT-SFT on HIV-1NL4-3 was performed as
described for pseudovirus. Briefly, 100 TCID50 viruses were used to infect
TZM-bl cells in the presence or absence of serially diluted peptides. Two
days post-infection, the cells were harvested and lysed in reporter lysis buf-
fer and the luciferase activity was measured.
Inhibition of 6-HB formation by peptides
A mouse monoclonal antibody specific for the gp41 6-HB (NC-1) was
obtained from Dr Shibo Jiang through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, National Institutes of Health.
The inhibitory activity of CHR peptides on the 6-HB formation was mea-
sured by a modified ELISA-based method as described previously.30
Briefly, a 96-well polystyrene plate (Costar, Corning Inc., Corning, NY,
USA) was coated with NC-1 (2 mg/mL in 0.1 M Tris, pH 8.8). A tested peptide
(sifuvirtide or MT-SFT) at graded concentrations was mixed with C34-biotin
(0.1 mM) and incubated with N36 (0.1 mM) at room temperature for
30 min. The mixture was then added to the NC-1-coated plate, followed
by incubation at room temperature for 30 min and washing with a wash-
ing buffer (PBS containing 0.1% Tween 20) three times. Then, horseradish
peroxidase-labelled streptavidin (Invitrogen) and the substrate
3,3,5,5-tetramethylbenzidine (Sigma) were added sequentially.
Absorbance at 450 nm was measured using an ELISA reader (Bio-Rad).
Induction of inhibitor-resistant HIV-1 variants
The in vitro selection of peptide inhibitor-resistant HIV-1 variants was per-
formed as described previously.24 Briefly, MT-4 cells were seeded at 1×104
in RPMI 1640 medium containing 10% fetal bovine serum on 12-well
plates. The molecular clone of HIV-1NL4-3 was used to infect the cells in
the presence or absence of diluted peptide inhibitors (sifuvirtide, MT-SFT,
C34 or MT-C34). The cells were incubated at 378C with 5% CO2 until
an extensive cytopathic effect was observed. The culture super-
natants were harvested and used for next passage on fresh MT-4 cells
with 1.5–2-fold increasing concentrations of peptide. The cells and super-
natant were harvested at regular timepoints and stored at 2808C.
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Results
The structure of the N-terminal M-T hook-capped SFT
To optimize sifuvirtide, we replaced the N-terminal serine of sifu-
virtide by residues methionine (M) and threonine (T), resulting in a
novel peptide named MT-SFT (Figure 1). We first performed crys-
tallographic studies to determine whether the incorporated residues
adopt the M-T hook structure. As shown in Figure 2(a), MT-SFT
formed a typical 6-HB structure with N36 as anticipated. The central
N36 trimeric coiled coil is fully wrapped by three MT-SFT peptides in
an antiparallel orientation. MT-SFT/N41 also formed a 6-HB struc-
ture, regardless that the counterpart of a C-terminal portion of
MT-SFT is unavailable on the N41 trimer (Figure 3a).
When performing the molecular replacement using the crystal
structure of sifuvirtide (without the M-T hook) as the searching
model, the resulting electron-density map showed strong Fo-Fc
positive peaks at the N-terminus of sifuvirtide. The positive densities
map clearly indicated the shape for a typical M-T hook structure.
After manual model building and refinements, we confirmed that
the N-terminal residues Met115 and Thr116 adopt the M-T hook
structure in both complexes (Figure 2a and b and Figure 3a and
b). Briefly, the threonine terminates the a-helical conformation of
MT-SFT by rotating its dihedral angle c nearly 1808. Consequently,
the N-termini of MT-SFT are directed away from the central coiled-
coil trimer. The conformation of the threonine is stabilized by an
important hydrogen bond between its side-chain hydroxyl group
and the backbone NH group of the downstream residues at i+3
position (Thr116–Thr119 in MT-SFT/N36, distance: 2.27 A˚, angle:
165.38; Thr116–Thr119 in MT-SFT/N41, distance: 2.76 A˚, angle:
165.18). As the result of the unusual conformation of Thr116, the
upstream methionine is then positioned on top of the left side of
the hydrophobic pocket on the NHR coiled-coil trimer, so that its
hydrophobic side chain can accommodate the hydrophobic groove
between the NHR and CHR helices, stabilizing the hydrophobic
pocket on the NHR trimer. The N-terminal portions of NHR-bound
MT-SFT could be perfectly superimposed on that of CP32, MT-C34
and MT-SC22EK, which contain the M-T hook structure.
The M-T hook greatly enhances the binding of sifuvirtide
Compared with the template peptide C34, the binding affinity of
sifuvirtide for the NHR target was markedly enhanced. Thus, it
was intriguing to know whether the M-T hook structure can fur-
ther enhance the binding of sifuvirtide. To this end, we applied
CD spectroscopy and ITC experiments. First, the a-helicity and
thermostability of the 6-HB core formed by MT-SFT and the
NHR-derived peptide N36 were measured by CD spectroscopy in
comparison with sifuvirtide and C34-based 6-HBs. The peptide
pairs (MT-SFT/N36, sifuvirtide/N36 and C34/N36) were mixed at
equal molar concentrations and incubated at 378C for 30 min.
As shown in Figure 4(a), the CD spectra of all three peptide pairs
displayed typical double minima at 208 and 222 nm, which indi-
cated the formation of the secondarya-helical structures. The ther-
mostability of each 6-HB, defined as the Tm value, was measured
(Figure 4b). Consistently, sifuvirtide-based 6-HB had a significantly
increased Tm value (72.28C) as compared with C34-based 6-HB
(65.38C). Strikingly, the Tm value of MT-SFT-based 6-HB was further
increased up to 81.38C. These results indicated that substitution of
the N-terminal residue serine by two M-T hook residues can mark-
edly increase the thermostability of the 6-HB conformation.
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Figure 2. Crystal structure of MT-SFT in complex with N36. (a) Upper part, a
ribbon model of the 6-HB structure formed by MT-SFT/N36. The N36 trimer is
coloured in blue and the MT-SFT peptides are coloured in yellow. The
N-terminus and C-terminus of one peptide are labelled. Lower part, the
red boxed portion of the above ribbon model of the 6-HB structure is
magnified. Residues Met115 and Thr116 form a hook-like structure
(highlighted in orange) that stabilizes the interaction between MT-SFT and
the NHR helices. Thr116 terminates the a-helical conformation of the
MT-SFT peptide. The hydroxyl group of the Thr116 side chain accepts a
hydrogen bond from the NH group of Thr119, directing the N-terminus of
MT-SFT away from the central NHR trimer. The side chain of Met115 covers
the hydrophobic pocket on the NHR trimer. The M-T hook and residues
involved in the interaction with the M-T hook are shown as stick models.
The dashed line indicates the hydrogen bond between Thr116 and Thr119.
(b) A portion of the 6-HB structure formed by MT-SFT/N36 is displayed as a
final stick model with the superimposed final 2Fo-Fc electron-density map
(1.5 s contour). The electron density for MT-SFT is shown as a yellow
mesh, the electron density for the N-terminal M-T hook is shown as an
orange mesh and the electron density for the N36 trimer is shown as a
blue mesh. The superimposed stick model is coloured with the same
scheme. The key residues forming the M-T hook are labelled.
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We then used the ITC technology to determine the thermo-
dynamic profiles of the molecular interaction between the inhibitors
and N36. The heat released or absorbed during the interaction
allowed an accurate determination of the binding constant (K),
reaction stoichiometry (N), enthalpy (DH) and entropy (DS). As
shown in Figure 5, the formation of 6-HBs by sifuvirtide and N36
(Figure 5a) or MT-SFTand N36 (Figure 5b) is a typical enthalpy-driven
reaction in which a large amount of heat is released. Compared with
sifuvirtide, the K value of MT-SFT increased 16.2-fold (from 6.8×105
to 1.1×107 M21), suggesting a largely increased binding affinity.
Therefore, the M-T hook structure critically determines the inter-
action of the inhibitors with the NHR target.
The M-T hook greatly improves the antiviral activity of
sifuvirtide
Based on our biophysical data, we were interested to compare the
anti-HIV activity of sifuvirtide and MT-SFT. In the HIV-1NL4-3
Env-mediated cell–cell fusion assay (Figure 6a), sifuvirtide and
MT-SFT had IC50 values of 3.4 and 1.0 nM, respectively, indicating
a 3.4-fold increase of potency for MT-SFT. In the single-cycle
entry assay (Figure 6b), sifuvirtide and MT-SFT inhibited HIV-1NL4-3
T116
C-peptides
M115
NHR trimer
W117
W120
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MT-SFT
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MT-SFT
M-T hook
NHR trimer
M-T hook
C'
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N'
N41 trimer
Figure 3. Crystal structure of MT-SFT in complex with N41. (a) A ribbon
model of the 6-HB structure formed by MT-SFT/N41. The N41 trimer is
coloured in grey and the MT-SFT peptides are coloured in yellow. The N-
and C-termini of the peptides are labelled. The M-T hook residues are
shown as stick models; they are coloured orange and are labelled. (b) A
portion of the 6-HB structure formed by MT-SFT/N41 is displayed as a
final atomic model with the superimposed final 2Fo-Fc electron-density
map (1.5 s contour). The electron density for N41 is shown in grey and
the electron density for MT-SFT is shown in blue. (c) Comparison of the
M-T hook structures. The N-terminal portions of N36-bound MT-SFT
(yellow), N41-bound MT-SFT (dark grey), CP32 (green), MT-C34 (blue)
and MT-SC22EK (red) are superimposed using Coot v0.6. The residues
involved in the interaction with the M-T hook are shown as stick models
and are labelled. The NHR trimer is coloured in grey.
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formed by N36 and CHR peptides are shown. Final concentration of each
peptide in PBS was 10 mM.
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pseudovirus with IC50 values of 3.2 and 0.9 nM, respectively, indi-
cating a 3.6-fold increase. For the wild-type HIV-1NL4-3 infection
(Figure 6c), sifuvirtide had an IC50 of 2.0 nM, whereas MT-SFT had
an IC50 of 0.6 nM, indicating a 3.3-fold increase. These results
demonstrated that the M-T hook residues can enhance the
anti-HIV activity of sifuvirtide .3-fold. We also showed that
MT-SFT possessed potent inhibitory activity against a panel of pri-
mary HIV-1 isolates (Table S2, available as Supplementary data
at JAC Online). To further understand the mechanism, we com-
pared the inhibitory activity of sifuvirtide and MT-SFT on the forma-
tion of the 6-HB structure. As shown in Figure 6(d), sifuvirtide
blocked 6-HB formation with an IC50 of 0.9 mM, whereas MT-SFT
had an IC50 value at 0.1 mM. Therefore, we concluded that the
M-T hook could confer the inhibitors with high-affinity binding cap-
acity to compete off the viral CHR, and thereby improving the
anti-HIV activity.
MT-SFT is a potent inhibitor of drug-resistant
HIV-1 variants
We previously found that the M-T hook structure-modified peptides
could inhibit drug-resistant HIV-1 variants more efficiently.28,29
Here, we utilized three panels of HIV-1 mutants to compare sifuvir-
tide and MT-SFT (Table 1). The Panel 1 and Panel 2 viruses are
selected by sifuvirtide and enfuvirtide, respectively, which have
been shown to confer high-level cross-resistance. The third panel
contains HIV-1 variants carrying naturally occurring mutations in
the NHR region that confer a high level of cross-resistance to several
potent HIV-1 fusion inhibitors, such as enfuvirtide, T1249 and
CP32M. As shown in Table 1, MT-SFT displayed higher potency
than sifuvirtide to inhibit various HIV-1 mutants. For example,
while sifuvirtide inhibited the Q40H mutant with an IC50 of
17.9 nM, MT-SFT had an IC50 of 1.9 nM, indicating a 9.4-fold
increased potency of MT-SFT. Particularly, while sifuvirtide showed
significantly reduced inhibitory activity against HIV-1 strains carry-
ing double mutations (the I37T/N43K and V38A/N42T mutants
from Panel 1 and the I37Q/V38M, I37S/V38N and I37V/V38T
mutants from the Panel 2), MT-SFT remained highly active. These
results verified that the M-T hook can significantly improve the abil-
ity of the inhibitors to inhibit drug-resistant HIV-1 variants.
High-affinity binding of MT-SFT to the NHR mutants
To gain insights into the mechanism of the M-T hook-modified
inhibitors possessing higher potency against drug-resistant HIV-1
variants, we compared the binding affinity of sifuvirtide and
MT-SFT for the NHR mutants. A panel of N36-based peptides car-
rying single (I37T, V38A, Q40H and N43K) or double (I37T/N43K
and V38A/N42T) NHR mutations were synthesized and applied
in the CD analysis. As shown in Figure 7, the NHR mutations
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could result in a sharp decrease in the thermostability of
sifuvirtide-based 6-HBs, such as I37T mutant (Tm¼57.28C) and
Q40H (Tm¼61.28C); however, the Tm values of MT-SFT-based
6-HBs could be significantly recovered, reaching a degree compar-
able (I37T, V38A, V38A/N42T) to or greater (Q40H, N43K, I37T/
N43K) than that of SFT/N36-based bundle (72.28C). Therefore,
we speculate that the M-T hook structure can compensate the
loss of binding affinity in the NHR mutants, thus preserving high
activity against sifuvirtide- and enfuvirtide-resistant HIV-1
variants.
The M-T hook significantly increases the genetic
barrier to drug resistance
We asked whether the M-T hook structure can confer the inhibitors
with a high genetic barrier to developing drug resistance. To
address this, we performed a series of passaging experiments to
generate virus that was resistant to sifuvirtide or MT-SFT. As
shown in Figure 8(a), sifuvirtide-resistant virus was obtained after
38 generations of passaging, at which time the concentration of
sifuvirtide reached up to 9600 nM; in sharp contrast, the virus did
not acquire obvious resistance to MT-SFT at the same timepoint.
We continued an additional 12 passages to select the virus resist-
ant to MT-SFT, leading to a drug concentration of 800 nM. Further,
we validated this finding by comparing the peptide pair C34 and
MT-C34 in parallel to induce the resistance. Consistently, the virus
culture could be reasonably recovered after 38 passages, wherein
the concentration of C34 was escalated up to 3200 nM (Figure 8b).
Consistently MT-C34 only approached 160 nM due to the difficulty
of passaging virus. Therefore, we could conclude that the modified
peptide inhibitors possessed an increased genetic barrier to the
development of resistance.
Discussion
By solving the crystal structure of the peptide CP32-based 6-HB, we
surprisingly identified that the hook-like structure attaches to one
side of the NHR pocket tightly, thus stabilizing the NHR-CHR inter-
action.27 Using peptides C34 and SC22EK as models, we have
demonstrated that the M-T hook conformation could be well pre-
served at the extreme N-termini of peptides and efficiently
strengthened the affinity of NHR–CHR interactions.28,29 In this
study, we incorporated the conserved hook residues in the
N-terminus of sifuvirtide and verified again a highly stable M-T
hook structure by crystallographic study. MT-SFT was cocrystallized
with two different NHR targets, N36 and N41. The N36 trimer can
accommodate the entire MT-SFT, whereas the N41 trimer only
accommodates the N-terminal part of the inhibitor and leaves
30% of C-terminal a-helices of MT-SFT overhanging (Figure 3).
However, this did not seem to confound the binding of MT-SFT to
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NHR targets, because both MT-SFT/N36 and MT-SFT/N41 pairs
formed stable 6-HB and yielded crystals that were diffracted to
high resolution. These data suggest that the crucial region on the
NHR is targeted by the N-terminal residues of MT-SFT, in which
the M-T hook and PBD play the critical roles. In addition, our findings
also suggest a strategy of further optimizing MT-SFT by shortening
the peptide from its C-terminus. Although sifuvirtide has already
been engineered for high binding, our biophysical data (CD and
ITC) indicated that addition of the M-T hook can further fortify the
inhibitor binding (Figures 4 and 5). Taken together, we believe that
the M-T hook presents a general structural feature when placed at
the N-terminus of the PBD of the CHR peptides. It is conceivable that
the M-T hook may integrate the PBD, thus synergistically enhancing
the interactions of CHR-derived inhibitors with the target NHR
sequences.
As the first and only clinically approved HIV-1 fusion inhibitor,
enfuvirtide has several prominent disadvantages limiting its wide
application.15,32 First, the antiviral activity of enfuvirtide is gener-
ally lower than that of other CHR-derived peptides. Second, it has
a short half-life in vivo, thus requiring a dosage of 90 mg twice
daily. Third, it has a relatively low genetic barrier to induction of
drug resistance. The emergence and spread of enfuvirtide-
resistant HIV-1 variants resulted in an increased number of
patients failing to respond to enfuvirtide treatment. The resist-
ance phenotype is associated mostly with substitutions in
amino acids 36–45 of the NHR, with three contiguous residues
(Gly36-Ile27-Val38) being a hotspot.10 – 12,33,34 To overcome the
problem of drug resistance, a number of strategies have been pur-
sued to develop novel peptide inhibitors with significantly improved
anti-HIV activity and pharmaceutical profiles.13 – 16,21,32 After
enfuvirtide, T-1249 was designed as a second-generation
fusion inhibitor by adding the PBD at its N-terminus,35 but
its clinical development was discontinued due to formulation
difficulties.36 – 38 Based on the C34 sequence, more potent pep-
tides were designed by introducing salt bridges that stabilize the
helical conformation of the inhibitors, such as sifuvirtide,22
SC34EK39 and T2635.40 Although these new-generation inhibitors
were effective against diverse enfuvirtide-resistant HIV-1 strains,
they also induced drug-resistant variants.24,41,42 Previously, the
in vitro selection of sifuvirtide-resistant HIV-1 variants identified
that most of the substitutions were confined to enfuvirtide-
resistant positions in the NHR of gp41, including amino acids
Ile37, Val38, Gln41 and Asn43 either singly or in combination,
and the mutant viruses showed variable degrees of cross-
resistance to enfuvirtide.24
Our previous studies demonstrated that the M-T hook-capped
peptides, such as MT-C34 and MT-SC22EK, had improved activity
against T20- and/or sifuvirtide-resistant HIV-1 variants.28,29 Here,
our data show that MT-SFT has significantly improved potency
compared with sifuvirtide to block 6-HB formation and inhibit
HIV-1 Env-mediated cell fusion, viral entry and infection, but
more impressively MT-SFT maintained high potency against a
large group of enfuvirtide- and sifuvirtide-resistant viruses, includ-
ing drug-induced and naturally occurring HIV-1 mutants (Table 1).
Consistently, our CD data revealed that MT-SFT interacted with the
corresponding NHR mutants with significantly higher stability as
compared with sifuvirtide (Figure 7). Nonetheless, the most signifi-
cant point of this study should be that the M-T hook-modified pep-
tides (MT-SFT and MT-C34) had a considerably higher genetic
barrier to developing drug resistance. During in vitro selection,
the escalating concentrations of the peptides sifuvirtide and C34
were able to easily select resistant viruses, in agreement with pre-
vious studies.24,43 In a sharp contrast, the addition of the M-T hook
residues (MT-SFT and MT-C34) markedly changed the resistance
profiles (Figure 8). We have also found that the M-T hook-modified
short-peptide inhibitor MT-SC22EK behaved with a similar pheno-
type (H. Chong, Z. Qiu, J. Sun, Y. Qiao and Y. He, unpublished data).
Taken together, we consider that the M-T hook structure can
endow the peptide fusion inhibitors with a high genetic barrier
to developing resistant HIV-1 variants, which provides an import-
ant feature for drug development. Recently, Eggink et al.44
described four mechanisms of drug resistance, including reduced
contact, steric obstruction, electrostatic repulsion and electrostatic
attraction. Our studies on the sifuvirtide resistance profile could
deduce several additional mechanisms, such as hydrogen bond
disruption and hydrophobic contact disruption.23,24 It is highly
interesting to know how the M-T hook structure changes the
Table 1. Inhibitory activity of SFT and MT-SFT against drug-resistant HIV-1
variants
HIV-1NL4-3 mutant
IC50 (nM)
n-fold (i.e.
SFT/MT-SFT)
P
valueaSFT MT-SFT
Panel 1
WT 2.4+0.1 0.8+0.1 3 0.004
I37T 8.4+1.0 2.0+0.3 4.2 ,0.001
V38A 8.7+2.1 1.9+0.6 4.6 0.003
V38M 6.2+0.8 1.6+0.3 3.9 ,0.001
Q40H 17.9+1.6 1.9+0.7 9.4 ,0.001
N43K 13.7+1.7 2.1+0.3 6.5 ,0.001
I37T/N43K 244.2+53.1 8.9+0.1 27.4 ,0.001
V38A/N42T 120.8+35.8 9.7+1.6 12.5 0.003
Panel 2
WT 2.4+0.3 0.9+0.1 2.7 ,0.001
L33S 6.5+0.4 1.8+0.5 3.6 ,0.001
I37Q/V38Q 10.8+2.5 3.0+0.6 3.6 0.003
I37Q/V38M 130.9+48.1 3.3+0.5 39.7 0.013
I37S/V38N 557.2+43.3 20.2+1.7 27.6 ,0.001
I37V/V38T 34.5+3.2 2.3+1.1 15 0.004
Panel 3
L33V 5.3+1.6 1.9+0.6 2.8 0.006
L34M 0.8+0.1 0.2+0.0 4 ,0.001
S35F 1.8+0.4 1.1+0.2 1.6 0.025
Q39R 4.6+0.5 1.4+0.1 3.3 ,0.001
L54M 2.0+0.6 0.5+0.1 4 0.007
Q56R 19.0+2.0 5.5+1.0 3.5 0.003
Q56K 10.8+2.8 2.0+0.2 5.4 0.003
L54M/Q56K 9.8+4.5 1.5+0.3 6.5 0.016
L54M/Q56R 9.1+1.1 3.9+0.7 2.3 0.001
L34M/L54M/Q56R 7.9+0.6 1.9+0.6 4.2 ,0.001
The HIV-1NL4-3 pseudoviruses were used for Panel 1 and the molecular
clones of HIV-1NL4-3 were used for Panels 2 and 3. WT, wild-type virus.
The data were derived from the results of three independent experiments
and are expressed as means+SD.
aStatistical analysis of the IC50 values of SFT and MT-SFT by Student’s t-test.
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resistance profiles of sifuvirtide and C34. From our structural stud-
ies, we could see that M-T hook binds the NHR target in a rather
unique way compared with any other region of the peptide.
Instead of binding to the groove between two adjacent NHR heli-
ces, the M-T hook binds to the side of the hydrophobic pocket as
well as the residues on its own PBD region. Therefore, it seems
that the M-T hook serves to strengthen the PBD – pocket
interaction rather than target novel sites on the NHR trimer. It
is well characterized that residues involving PBD–pocket inter-
action are the most conserved residues during HIV-1 evolution;
the mutation of these residues is often lethal to the virus. Thus,
the balance between virus survival and drug resistance becomes
hard to maintain and the genetic barrier to drug resistance against
the M-T hook increases. Although MT-SFTand MT-C34 are currently
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undergoing a delayed selection procedure, they may be gradually
escalated to higher concentrations thus resulting in the high-level
resistant HIV-1 mutants. We expect to explore the mechanism of
HIV-1 resistance to the M-T hook-based peptides by multiple
approaches, which would be helpful for understanding the
mechanisms of HIV-1 fusion and for designing novel fusion
inhibitors.
In conclusion, the significance of our studies includes three
aspects. First, we have verified that the M-T hook structure is a
general feature of CHR-derived inhibitors. Second, the M-T hook
structure plays a vital role for designing fusion inhibitors against
enfuvirtide- and sifuvirtide-resistant HIV-1 mutants. Third, the
M-T hook-based HIV-1 fusion inhibitors have a high genetic barrier
to developing drug resistance.
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